UBS Group AG Has $10.93 Million Stake in Clarivate PLC $CLVT

UBS Group AG grew its holdings in Clarivate PLC (NYSE:CLVT) by 21.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,271,921 shares of the company’s stock after purchasing an additional 580,765 shares during the period. UBS Group AG owned about 0.49% of Clarivate worth $10,928,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CLVT. Balyasny Asset Management L.P. increased its holdings in shares of Clarivate by 827.6% in the 3rd quarter. Balyasny Asset Management L.P. now owns 4,882,593 shares of the company’s stock valued at $18,700,000 after purchasing an additional 4,356,232 shares during the period. Bank of America Corp DE increased its holdings in shares of Clarivate by 506.9% in the 2nd quarter. Bank of America Corp DE now owns 2,870,668 shares of the company’s stock valued at $12,344,000 after purchasing an additional 2,397,670 shares during the period. Man Group plc increased its holdings in shares of Clarivate by 228.1% in the 2nd quarter. Man Group plc now owns 3,091,139 shares of the company’s stock valued at $13,292,000 after purchasing an additional 2,148,943 shares during the period. LSV Asset Management acquired a new position in shares of Clarivate in the 3rd quarter valued at about $8,072,000. Finally, American Century Companies Inc. increased its holdings in shares of Clarivate by 20.6% in the 3rd quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock valued at $38,200,000 after purchasing an additional 1,706,306 shares during the period. Institutional investors and hedge funds own 85.72% of the company’s stock.

Analysts Set New Price Targets

CLVT has been the topic of a number of research reports. Barclays dropped their target price on Clarivate from $4.00 to $2.40 and set an “underweight” rating on the stock in a report on Wednesday, February 25th. Citigroup dropped their target price on Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a report on Friday, March 27th. Finally, Royal Bank Of Canada dropped their price objective on Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $3.22.

Clarivate Trading Up 3.6%

NYSE:CLVT opened at $2.43 on Friday. The stock’s 50 day moving average price is $2.54 and its 200 day moving average price is $2.88. Clarivate PLC has a 52 week low of $1.66 and a 52 week high of $4.77. The company has a market capitalization of $1.55 billion, a P/E ratio of -11.55 and a beta of 1.41. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.84 and a current ratio of 0.84.

Clarivate (NYSE:CLVT) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.The firm had revenue of $585.50 million for the quarter, compared to the consensus estimate of $569.50 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, research analysts forecast that Clarivate PLC will post 0.65 EPS for the current fiscal year.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.